News | December 10, 2023
Briefs: GlaxoSmithKline Pharmaceuticals and Dr. Reddy's Laboratories
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
The company has reported total income of Rs. 815.11 crores during the period ended March 31, 2023
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
General Medicine grows 5% and Vaccines 10% led by Shingrix
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)